Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2014 and Temozolomide in Recurrent Glioblastoma
NCT02619864Phase 1Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Dec 2016
- Primary completion
- Mar 2019
- Countries
- 1
01
Overview
Phase 1, open-label trial of vistusertib in glioblastoma multiforme (GBM), sponsored by Canadian Cancer Trials Group. Primary endpoint: Recommended Phase II Dose at Day 0. Started Dec 2016; status: completed.
02
Drugs
vistusertib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02619864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02619864.